Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
3 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company filed its application with the FDA on September 30, 2026, and expects to hear on acceptance within about two months.
SEC filing